KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBT Margin for 15 consecutive years, with 0.9% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 1605.0% to 0.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.82%, a 2161.0% decrease, with the full-year FY2025 number at 6.82%, down 2161.0% from a year prior.
  • EBT Margin was 0.9% for Q4 2025 at Supernus Pharmaceuticals, up from 30.17% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 25.58% in Q3 2024 to a low of 30.17% in Q3 2025.
  • A 5-year average of 6.01% and a median of 6.54% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: skyrocketed 2826bps in 2024, then tumbled -5575bps in 2025.
  • Supernus Pharmaceuticals' EBT Margin stood at 1.29% in 2021, then skyrocketed by 1529bps to 21.0% in 2022, then crashed by -97bps to 0.6% in 2023, then soared by 2414bps to 15.15% in 2024, then tumbled by -106bps to 0.9% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBT Margin are 0.9% (Q4 2025), 30.17% (Q3 2025), and 10.07% (Q2 2025).